Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
Status:
Not yet recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally
advanced esophageal cancer (EC). However, as high as more than 40% of EC patients experienced
locoregional recurrence after concurrent CRT. Immunotherapy targeting the PD-1/PD-L1
checkpoints has demonstrated promising activity in advanced EC. Recently, the combination of
immunotherapy with CRT has emerged as a promising strategy to improve clinical outcomes in
EC. The aim of this study was to evaluate whether the efficacy of tislelizumab (an anti-PD-1
antibody) plus induction chemotherapy followed by concurrent chemoradiotherapy would achieve
a ≥71% 1-year progression-free survival rate, surpassing the historical 56% rate
(NCT02403531) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).